Meritage Portfolio Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Meritage Portfolio Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$95.3K	Buy	227,000 +50,000	+28%	+$26.5K	0.01%	316
2025 Q3	$119K	Buy	177,000 +50,000	+39%	+$27K	0.01%	324
2025 Q2	$68.7K	Buy	127,000 +34,500	+37%	+$20.5K	﹤0.01%	317
2025 Q1	$60.7K	Buy	92,500 +7,500	+9%	+$7.94K	﹤0.01%	313
2024 Q4	$86.7K	Hold	85,000	–	–	0.01%	320
2024 Q3	$74K	Buy	85,000 +6,740	+9%	+$4.94K	﹤0.01%	328
2024 Q2	$28K	Hold	78,260	–	–	﹤0.01%	327
2024 Q1	$52K	Hold	78,260	–	–	﹤0.01%	335
2023 Q4	$43K	Hold	78,260	–	–	﹤0.01%	330
2023 Q3	$47K	Hold	78,260	–	–	﹤0.01%	323
2023 Q2	$102K	Hold	78,260	–	–	0.01%	335
2023 Q1	$138K	Hold	78,260	–	–	0.01%	307
2022 Q4	$246K	Hold	78,260	–	–	0.02%	281
2022 Q3	$383K	Buy	+78,260	New	+$402K	0.03%	229

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meritage Portfolio Management's SGMO Position: Q4 2025 in Review

Meritage Portfolio Management increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 28% in Q4 2025, buying an estimated $26.5K and bringing the position to 227,000 shares worth $95.3K. The position accounts for 0.01% of the portfolio, ranked #316.

Meritage Portfolio Management first reported a position in SGMO in Q3 2022 and has held it in 14 quarters since. The position peaked at $383K in Q3 2022. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

Meritage Portfolio Management held 227,000 shares of SANGAMO THERAPEUTICS INC worth $95.3K as of Q4 2025.
Meritage Portfolio Management bought 50,000 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $26.5K.
SANGAMO THERAPEUTICS INC made up 0.01% of Meritage Portfolio Management's portfolio in Q4 2025, its #316 holding.
Meritage Portfolio Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2022 and has held it in 14 quarters since.
Meritage Portfolio Management's SANGAMO THERAPEUTICS INC position peaked at $383K in Q3 2022.
105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.